GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced ...

Mouth taping, intended to promote nasal breathing during sleep, is popular despite limited scientific support. It may reduce ...

Nosebleeds are common and often caused by dry air, allergies, or minor trauma, and they can usually be stopped by applying ...